Francois Cedric's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Aug 29, 2025
- Accession no.
- 0001193125-25-192797
- Filed
- Aug 29, 2025
- Trade date
- Aug 27-28, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $6.35M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Francois CedricCIK 0001658080 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.78 - $28.49, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 - $28.68, inclusive.
Referenced by the price of 1 transaction in Table I.